November 18, 2019
Ken Romeril, CEO Myeloma New Zealand Charitable Trust invites you to the Myeloma New Zealand Christmas Function. Wednesday 11 December, 5.00pm at BNZ Partners Centre, Level 10 Ricoh House, 1 Victoria Street, Wellington. Guest speaker: Dr Henry Chan, Consultant Haematologist, North Shore Hospital “Latest myeloma update from recent international conferences” RSVP by Friday 6 December...
Continue Reading
There are issues involving Pharmac and how they fund medicines – Pharmac does not adopt international guidelines; it does not set a timeframe by which it will be decided if a medicine is efficacious and another timeframe when it will endeavour to fund a medicine if it is deemed to be efficacious; it needs to...
Continue Reading
The U.S. Food and Drug Administration (FDA) approved the quadruplet regimen consisting of daratumumab, bortezomib, thalidomide, and dexamethasone to treat adult patients with newly diagnosed multiple myeloma who are eligible for autologous hematopoietic cell transplantation. This approval is based on data from the open-label, randomized phase III CASSIOPEIA trial, which compared induction and consolidation treatment...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand